KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Depreciation & Amortization (CF) (2017 - 2025)

Guardant Health's Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $10.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 3.86% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $39.7 million, down 6.25%, while the annual FY2025 figure was $39.7 million, 6.25% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $10.0 million at Guardant Health, up from $9.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $11.0 million in Q3 2023 and bottomed at $5.0 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $10.1 million (2022), against an average of $9.2 million.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 76.89% in 2022 before it fell 11.23% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $6.1 million in 2021, then surged by 66.98% to $10.2 million in 2022, then rose by 6.87% to $10.9 million in 2023, then fell by 3.81% to $10.5 million in 2024, then decreased by 3.86% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Depreciation & Amortization (CF) are $10.0 million (Q4 2025), $9.4 million (Q3 2025), and $10.0 million (Q2 2025).